Related references
Note: Only part of the references are listed.Broadly active zinc finger protein-guided transcriptional activation of HIV-1
Tristan A. Scott et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2021)
Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives
Wendy Dong et al.
VIRUSES-BASEL (2021)
Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy
Qiaoqiao Xiao et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2019)
Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART
Nadine Bachmann et al.
NATURE COMMUNICATIONS (2019)
Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir
Pavitra Roychoudhury et al.
BMC BIOLOGY (2018)
No Effect of Pegylated Interferon-α on Total HIV-1 DNA Load in HIV-1/HCV Coinfected Patients
Victoria P. Strouvelle et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Tackling HIV Persistence: Pharmacological versus CRISPR-Based Shock Strategies
Gilles Darcis et al.
VIRUSES-BASEL (2018)
Comprehensive off-target analysis of dCas9-SAM-mediated HIV reactivation via long noncoding RNA and mRNA profiling
Yonggang Zhang et al.
BMC MEDICAL GENOMICS (2018)
Prediction of Human Immunodeficiency Virus Type 1 Subtype-Specific Off-Target Effects Arising from CRISPR-Cas9 Gene Editing Therapy
Robert W. Link et al.
CRISPR JOURNAL (2018)
HIV integration sites in latently infected cell lines: evidence of ongoing replication
Jori Symons et al.
RETROVIROLOGY (2017)
CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes
Eric Ehrke-Schulz et al.
SCIENTIFIC REPORTS (2017)
Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex
Sheena M. Saayman et al.
MOLECULAR THERAPY (2016)
CRISPR-mediated Activation of Latent HIV-1 Expression
Prajit Limsirichai et al.
MOLECULAR THERAPY (2016)
Specific Reactivation of Latent HIV-1 by dCas9-SunTag-VP64-mediated Guide RNA Targeting the HIV-1 Promoter
Haiyan Ji et al.
MOLECULAR THERAPY (2016)
Comparison of Cas9 activators in multiple species
Alejandro Chavez et al.
NATURE METHODS (2016)
Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?
Thomas A. Rasmussen et al.
CURRENT OPINION IN HIV AND AIDS (2016)
Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems
Julia K. Bialek et al.
PLOS ONE (2016)
A Hardwired HIV Latency Program
Brandon S. Razooky et al.
CELL (2015)
The New State of the Art: Cas9 for Gene Activation and Repression
Marie F. La Russa et al.
MOLECULAR AND CELLULAR BIOLOGY (2015)
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Silvana Konermann et al.
NATURE (2015)
Highly efficient Cas9-mediated transcriptional programming
Alejandro Chavez et al.
NATURE METHODS (2015)
CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs
Yonggang Zhang et al.
SCIENTIFIC REPORTS (2015)
Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
Xiao-Hui Zhang et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging
Marvin E. Tanenbaum et al.
CELL (2014)
Emerging strategies to deplete the HIV reservoir
Nancie M. Archin et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2014)
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Lei S. Qi et al.
CELL (2013)
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Luke A. Gilbert et al.
CELL (2013)
RNA-guided gene activation by CRISPR-Cas9-based transcription factors
Pablo Perez-Pinera et al.
NATURE METHODS (2013)
Quantitation of Gene Expression in Formaldehyde-Fixed and Fluorescence-Activated Sorted Cells
Julia N. Russell et al.
PLOS ONE (2013)
Cell line-dependent variability in HIV activation employing DNMT inhibitors
Guerau Fernandez et al.
VIROLOGY JOURNAL (2010)
Identification of Gammaretroviruses Constitutively Released from Cell Lines Used for Human Immunodeficiency Virus Research
Yasuhiro Takeuchi et al.
JOURNAL OF VIROLOGY (2008)
Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef
M Fischer et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement
B Roscic-Mrkic et al.
BLOOD (2003)
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro
A Jordan et al.
EMBO JOURNAL (2003)
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
XP Wei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
TW Chun et al.
NATURE MEDICINE (2000)
Share Paper
